GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » PT Soho Global Health Tbk (ISX:SOHO) » Definitions » EBITDA

PT Soho Global Health Tbk (ISX:SOHO) EBITDA : Rp613,102 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is PT Soho Global Health Tbk EBITDA?

PT Soho Global Health Tbk's EBITDA for the three months ended in Sep. 2024 was Rp165,602 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was Rp613,102 Mil.

During the past 12 months, the average EBITDA Growth Rate of PT Soho Global Health Tbk was 27.60% per year. During the past 3 years, the average EBITDA Growth Rate was 18.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 5 years, the highest 3-Year average EBITDA Growth Rate of PT Soho Global Health Tbk was 22.20% per year. The lowest was 18.20% per year. And the median was 20.20% per year.

PT Soho Global Health Tbk's EBITDA per Share for the three months ended in Sep. 2024 was Rp13.05. Its EBITDA per share for the trailing twelve months (TTM) ended in Sep. 2024 was Rp48.31.

During the past 12 months, the average EBITDA per Share Growth Rate of PT Soho Global Health Tbk was 27.60% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 5.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 5 years, the highest 3-Year average EBITDA per Share Growth Rate of PT Soho Global Health Tbk was 22.20% per year. The lowest was 5.40% per year. And the median was 13.80% per year.


PT Soho Global Health Tbk EBITDA Historical Data

The historical data trend for PT Soho Global Health Tbk's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PT Soho Global Health Tbk EBITDA Chart

PT Soho Global Health Tbk Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA
276,174.00 312,415.00 740,591.00 503,447.00 515,859.00

PT Soho Global Health Tbk Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 156,531.00 136,051.00 173,270.00 138,179.00 165,602.00

Competitive Comparison of PT Soho Global Health Tbk's EBITDA

For the Medical Distribution subindustry, PT Soho Global Health Tbk's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PT Soho Global Health Tbk's EV-to-EBITDA Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, PT Soho Global Health Tbk's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PT Soho Global Health Tbk's EV-to-EBITDA falls into.


';

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

PT Soho Global Health Tbk's EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

PT Soho Global Health Tbk's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2023, PT Soho Global Health Tbk's EBITDA was Rp515,859 Mil.

PT Soho Global Health Tbk's EBITDA for the quarter that ended in Sep. 2024 is calculated as

PT Soho Global Health Tbk's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Sep. 2024, PT Soho Global Health Tbk's EBITDA was Rp165,602 Mil.

EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp613,102 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

PT Soho Global Health Tbk  (ISX:SOHO) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


PT Soho Global Health Tbk EBITDA Related Terms

Thank you for viewing the detailed overview of PT Soho Global Health Tbk's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


PT Soho Global Health Tbk Business Description

Traded in Other Exchanges
N/A
Address
Jalan Rawa Sumur II Kav BB No. 3, Kawasan Industri Pulogadung, Kel., Jatinegara, Kec. Cakung, Jakarta Timur, Jakarta, IDN, 13930
PT Soho Global Health Tbk is a healthcare company operating in the areas of natural/herbal health care products and services. The company manufactures and distributes pharmaceutical products to herbal cures, proprietary medicines and health foods under various brand names such as Curcuma Plus; Curcuma Plus Milk; Imboost; Fitkom; Diapet; Laxing; Lelap; Asthma Soho; and Sohobion. Its segment includes Distribution; Professional product; Consumer health; Alliance and others. The company generates maximum revenue from the Distribution segment.